Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diagnostic Pathology
Published in: Diagnostic Pathology 1/2015

Open Access 01-12-2015 | Research

RETRACTED ARTICLE: Downregulated Poly-C binding protein-1 is a novel predictor associated with poor prognosis in Acute Myeloid Leukemia

Authors: Meifeng Zhou, Xiuzhen Tong

Published in: Diagnostic Pathology | Issue 1/2015

Login to get access

Abstract

Background

Depletion of Poly-C binding protein-1(PCBP1) is implicated in various human malignancies. However, the underlying biological effect of PCBP1 in cancers, including acute myeloid leukemia (AML), still remains elusive. The purpose of this study was to examine the expression and clinical outcome of PCBP1in acute myeloid leukemia.

Methods

Bone marrow fluids of 88 newly diagnosed AML patients were sampled, and the PCBP1 mRNA expression level was evaluated using quantitative RT-PCR. The association between PCBP1 expression and clinicopathological features or the survival status of the patients was assessed by Chi-square test and Kaplan-Meier method.

Results

Comparing newly diagnosed AML patients to normal healthy donors, PCBP1 expression was significantly decreased in AML patients (P < 0.001). Conversely, PCBP1 expression had accordingly recovered back to normal in patients with complete remission (P < 0.001). Clinical feature analyses showed that PCBP1 expression was negatively correlated with white blood cell count (P = 0.024). In addition, patients with low PCBP1 expression had poor disease-free survival (11.8 % vs. 45.3 %; P = 0.01) and overall survival (18.2 % vs. 42.4 %; P = 0.032), respectively.

Conclusions

Taken together, our results showed for the first time that expression of PCBP1 was down-regulated in newly diagnosed AML patients and might be an independent prognostic marker in AML and should to be further investigated.
Literature
1.
O'Donnell MR, Abboud CN, Altman J, Appelbaum FR, Coutre SE, Damon LE, et al. Acute myeloid leukemia. J Natl Compr Canc Netw. 2011;9(3):280–317.CrossRefPubMed
2.
Conway O'Brien E, Prideaux S, Chevassut T. The epigenetic landscape of acute myeloid leukemia. Adv Hematol. 2014;2014:103175.PubMedPubMedCentral
3.
4.
5.
Banerji V, Frumm SM, Ross KN, Li LS, Schinzel AC, Hahn CK, et al. The intersection of genetic and chemical genomic screens identifies GSK-3alpha as a target in human acute myeloid leukemia. J Clin Invest. 2012;122(3):935–47.CrossRefPubMedPubMedCentral
6.
Frohling S, Scholl C, Gilliland DG, Levine RL. Genetics of myeloid malignancies: pathogenetic and clinical implications. J Clin Oncol. 2005;23(26):6285–95.CrossRefPubMed
7.
Kralik JM, Kranewitter W, Boesmueller H, Marschon R, Tschurtschenthaler G, Rumpold H, et al. Characterization of a newly identified ETV6-NTRK3 fusion transcript in acute myeloid leukemia. Diagn Pathol. 2011;6:19.CrossRefPubMedPubMedCentral
8.
Wander SA, Levis MJ, Fathi AT. The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond. Ther Adv Hematol. 2014;5(3):65–77.CrossRefPubMedPubMedCentral
9.
Masetti R, Pigazzi M, Togni M, Astolfi A, Indio V, Manara E, et al. CBFA2T3-GLIS2 fusion transcript is a novel common feature in pediatric, cytogenetically normal AML, not restricted to FAB M7 subtype. Blood. 2013;121(17):3469–72.CrossRefPubMed
10.
Masetti R, Togni M, Astolfi A, Pigazzi M, Manara E, Indio V, et al. DHH-RHEBL1 fusion transcript: a novel recurrent feature in the new landscape of pediatric CBFA2T3-GLIS2-positive acute myeloid leukemia. Oncotarget. 2013;4(10):1712–20.CrossRefPubMedPubMedCentral
11.
Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood. 2005;106(4):1154–63.CrossRefPubMed
12.
13.
14.
Ma QL, Wang JH, Wang YG, Hu C, Mu QT, Yu MX, et al. High IDH1 expression is associated with a poor prognosis in cytogenetically normal acute myeloid leukemia. Int J Cancer. 2014.
15.
16.
Huo LR, Zhong N. Identification of transcripts and translatants targeted by overexpressed PCBP1. Biochim Biophys Acta. 2008;1784(11):1524–33.CrossRefPubMed
17.
Wang H, Vardy LA, Tan CP, Loo JM, Guo K, Li J, et al. PCBP1 suppresses the translation of metastasis-associated PRL-3 phosphatase. Cancer Cell. 2010;18(1):52–62.CrossRefPubMed
18.
Lian WX, Yin RH, Kong XZ, Zhang T, Huang XH, Zheng WW, et al. THAP11, a novel binding protein of PCBP1, negatively regulates CD44 alternative splicing and cell invasion in a human hepatoma cell line. FEBS Lett. 2012;586(10):1431–8.CrossRefPubMed
19.
Zhang T, Huang XH, Dong L, Hu D, Ge C, Zhan YQ, et al. PCBP-1 regulates alternative splicing of the CD44 gene and inhibits invasion in human hepatoma cell line HepG2 cells. Mol Cancer. 2010;9:72.CrossRefPubMedPubMedCentral
20.
Yang X, Zhang Z, Jia C, Li J, Yin L, Jiang S. The relationship between expression of c-ras, c-erbB-2, nm23, and p53 gene products and development of trophoblastic tumor and their predictive significance for the malignant transformation of complete hydatidiform mole. Gynecol Oncol. 2002;85(3):438–44.CrossRefPubMed
21.
Pillai MR, Chacko P, Kesari LA, Jayaprakash PG, Jayaram HN, Antony AC. Expression of folate receptors and heterogeneous nuclear ribonucleoprotein E1 in women with human papillomavirus mediated transformation of cervical tissue to cancer. J Clin Pathol. 2003;56(8):569–74.CrossRefPubMedPubMedCentral
22.
Shi Z, Zhang T, Long W, Wang X, Zhang X, Ling X, et al. Down-regulation of poly(rC)-binding protein 1 correlates with the malignant transformation of hydatidiform moles. Int J Gynecol Cancer. 2012;22(7):1125–9.CrossRefPubMed
23.
Zhang HY, Dou KF. PCBP1 is an important mediator of TGF-beta-induced epithelial to mesenchymal transition in gall bladder cancer cell line GBC-SD. Mol Biol Rep. 2014;41(8):5519–24.CrossRefPubMed
24.
Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937–51.CrossRefPubMed
25.
Yanada M, Takeuchi J, Sugiura I, Akiyama H, Usui N, Yagasaki F, et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol. 2006;24(3):460–6.CrossRefPubMed
26.
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 2001;25(4):402–8.CrossRef
27.
Han N, Li W, Zhang M. The function of the RNA-binding protein hnRNP in cancer metastasis. J Cancer Res Ther. 2013;9:S129–34.CrossRefPubMed
28.
Carpenter B, MacKay C, Alnabulsi A, MacKay M, Telfer C, Melvin WT, et al. The roles of heterogeneous nuclear ribonucleoproteins in tumour development and progression. Biochim Biophys Acta. 2006;1765(2):85–100.PubMed
29.
Eder S, Lamkowski A, Priller M, Port M, Steinestel K. Radiosensitization and downregulation of heterogeneous nuclear ribonucleoprotein K (hnRNP K) upon inhibition of mitogen/extracellular signal-regulated kinase (MEK) in malignant melanoma cells. Oncotarget. 2015.
30.
Ritchie SA, Pasha MK, Batten DJP, Sharma RK, Olson DJH, Ross ARS, et al. Identification of the SRC pyrimidine-binding protein (SPy) as hnRNP K: implications in the regulation of SRC1A transcription. Nucleic Acids Research. 2003;31(5):1502–13.CrossRefPubMedPubMedCentral
31.
Evans JR, Mitchell SA, Spriggs KA, Ostrowski J, Bomsztyk K, Ostarek D, et al. Members of the poly (rC) binding protein family stimulate the activity of the c-myc internal ribosome entry segment in vitro and in vivo. Oncogene. 2003;22(39):8012–20.CrossRefPubMed
32.
Han W, Xin Z, Zhao Z, Bao W, Lin X, Yin B, et al. RNA-binding protein PCBP2 modulates glioma growth by regulating FHL3. J Clin Invest. 2013;123(5):2103–18.CrossRefPubMedPubMedCentral
33.
Hu CE, Liu YC, Zhang HD, Huang GJ. The RNA-binding protein PCBP2 facilitates gastric carcinoma growth by targeting miR-34a. Biochem Biophys Res Commun. 2014;448(4):437–42.CrossRefPubMed
34.
Cloke B, Shah K, Kaneda H, Lavery S, Trew G, Fusi L, et al. The poly(c)-binding protein-1 regulates expression of the androgen receptor. Endocrinology. 2010;151(8):3954–64.CrossRefPubMed
35.
Chaudhury A, Hussey GS, Ray PS, Jin G, Fox PL, Howe PH. TGF-beta-mediated phosphorylation of hnRNP E1 induces EMT via transcript-selective translational induction of Dab2 and ILEI. Nat Cell Biol. 2010;12(3):286–93.CrossRefPubMedPubMedCentral
36.
Huo LR, Ju W, Yan M, Zou JH, Yan W, He B, et al. Identification of differentially expressed transcripts and translatants targeted by knock-down of endogenous PCBP1. Biochim Biophys Acta. 2010;1804(10):1954–64.CrossRefPubMed
37.
Nishinakamura H, Minoda Y, Saeki K, Koga K, Takaesu G, Onodera M, et al. An RNA-binding protein alphaCP-1 is involved in the STAT3-mediated suppression of NF-kappaB transcriptional activity. Int Immunol. 2007;19(5):609–19.CrossRefPubMed
38.
Shi H, Zhou M, Tong X, Wang H. The function and mechanism of PCBP1 in gene regulation. Chemistry of Life. 2013;33(5):535–42.
39.
40.
Giles KM, Daly JM, Beveridge DJ, Thomson AM, Voon DC, Furneaux HM, et al. The 3 '-untranslated region of p21(WAF1) mRNA is a composite cis-acting sequence bound by RNA-binding proteins from breast cancer cells, including HuR and poly(C)-binding protein. J Biol Chem. 2003;278(5):2937–46.CrossRefPubMed
41.
Qu S, Liu B, Guo X, Shi H, Zhou M, Li L, et al. Independent oncogenic and therapeutic significance of phosphatase PRL-3 in FLT3-ITD-negative acute myeloid leukemia. Cancer. 2014;120(14):2130–41.CrossRefPubMed
42.
Park JE, Yuen HF, Zhou JB, Al-Aidaroos AQ, Guo K, Valk PJ, et al. Oncogenic roles of PRL-3 in FLT3-ITD induced acute myeloid leukaemia. EMBO Mol Med. 2013;5(9):1351–66.CrossRefPubMedPubMedCentral
43.
Thakur S, Nakamura T, Calin G, Russo A, Tamburrino JF, Shimizu M, et al. Regulation of BRCA1 transcription by specific single-stranded DNA binding factors. Mol Cell Biol. 2003;23(11):3774–87.CrossRefPubMedPubMedCentral
Metadata
Title
RETRACTED ARTICLE: Downregulated Poly-C binding protein-1 is a novel predictor associated with poor prognosis in Acute Myeloid Leukemia
Authors
Meifeng Zhou
Xiuzhen Tong
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Diagnostic Pathology / Issue 1/2015
Electronic ISSN: 1746-1596
DOI
https://doi.org/10.1186/s13000-015-0377-y

Other articles of this Issue 1/2015

Diagnostic Pathology 1/2015 Go to the issue

Case Report

Spontaneous regression of plasmablastic lymphoma in an elderly human immunodeficiency virus (HIV)-negative patient

Review

Pathologic manifestations of levamisole-adulterated cocaine exposure

Research

CK19 is a sensitive marker for yolk sac tumours of the testis

Research

Paeoniflorin exerts a nephroprotective effect on concanavalin A-induced damage through inhibition of macrophage infiltration

Retraction Note

Retraction Note: New proposal for the serum ascites albumin gradient cut-off value in Chinese ascitic patients

Research

Overexpression of Trps1 contributes to tumor angiogenesis and poor prognosis of human osteosarcoma